Published in Gastroenterology on November 18, 2009
Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflamm (2010) 2.18
The health benefits of dietary fiber: beyond the usual suspects of type 2 diabetes mellitus, cardiovascular disease and colon cancer. Metabolism (2012) 1.31
Mechanisms of obesity-induced gastrointestinal neoplasia. Gastroenterology (2013) 1.18
CODEX-aligned dietary fiber definitions help to bridge the 'fiber gap'. Nutr J (2014) 1.12
Functional consequences of microbial shifts in the human gastrointestinal tract linked to antibiotic treatment and obesity. Gut Microbes (2013) 1.07
Colon transit time according to physical activity and characteristics in South Korean adults. World J Gastroenterol (2013) 0.99
Colon transit time according to physical activity level in adults. J Neurogastroenterol Motil (2012) 0.99
Dietary fiber future directions: integrating new definitions and findings to inform nutrition research and communication. Adv Nutr (2013) 0.97
What do we know about dietary fiber intake in children and health? The effects of fiber intake on constipation, obesity, and diabetes in children. Adv Nutr (2012) 0.94
The short-chain fatty acid uptake fluxes by mice on a guar gum supplemented diet associate with amelioration of major biomarkers of the metabolic syndrome. PLoS One (2014) 0.89
Plantain peel - a potential source of antioxidant dietary fibre for developing functional cookies. J Food Sci Technol (2015) 0.88
Ranking the impact of human health disorders on gut metabolism: systemic lupus erythematosus and obesity as study cases. Sci Rep (2015) 0.87
Dietary fiber is positively associated with cognitive control among prepubertal children. J Nutr (2014) 0.85
Major cereal grain fibers and psyllium in relation to cardiovascular health. Nutrients (2013) 0.83
Successful development of satiety enhancing food products: towards a multidisciplinary agenda of research challenges. Crit Rev Food Sci Nutr (2012) 0.83
Mechanism of Butyrate Stimulation of Triglyceride Storage and Adipokine Expression during Adipogenic Differentiation of Porcine Stromovascular Cells. PLoS One (2015) 0.81
A comparison of satiety, glycemic index, and insulinemic index of wheat-derived soft pretzels with or without soy. Food Funct (2011) 0.79
Nutrigenomics and personalized diets: What will they mean for food? Annu Rev Food Sci Technol (2011) 0.79
Green and Black Cardamom in a Diet-Induced Rat Model of Metabolic Syndrome. Nutrients (2015) 0.78
Enzymatic polishing of cereal grains for improved nutrient retainment. J Food Sci Technol (2014) 0.77
Effects of water extracts of Graptopetalum paraguayense on blood pressure, fasting glucose, and lipid profiles of subjects with metabolic syndrome. Biomed Res Int (2013) 0.76
Bamboo shoot fiber prevents obesity in mice by modulating the gut microbiota. Sci Rep (2016) 0.76
Therapeutic effects of soluble dietary fiber consumption on type 2 diabetes mellitus. Exp Ther Med (2016) 0.75
Long-term antihypertensive effect of a soluble cocoa fiber product in spontaneously hypertensive rats. Food Nutr Res (2016) 0.75
Polyphenol-rich strawberry extract (PRSE) shows in vitro and in vivo biological activity against invasive breast cancer cells. Sci Rep (2016) 0.75
Comparison of Segmental Colon Transit Time With Total Energy Expenditure in Psychiatry Unit Patients. Gastroenterol Nurs (2015) 0.75
Protection against the Metabolic Syndrome by Guar Gum-Derived Short-Chain Fatty Acids Depends on Peroxisome Proliferator-Activated Receptor γ and Glucagon-Like Peptide-1. PLoS One (2015) 0.75
Aerobic exercise improves gastrointestinal motility in psychiatric inpatients. World J Gastroenterol (2014) 0.75
The Obesity-Impulsivity Axis: Potential Metabolic Interventions in Chronic Psychiatric Patients. Front Psychiatry (2017) 0.75
Effects of Dietary Fibre (Pectin) and/or Increased Protein (Casein or Pea) on Satiety, Body Weight, Adiposity and Caecal Fermentation in High Fat Diet-Induced Obese Rats. PLoS One (2016) 0.75
The Gastrointestinal Tract as an Integrator of Mechanical and Hormonal Response to Nutrient Ingestion. Diabetes (2017) 0.75
Changes in Gut Microbial Ecology and Immunological Responses of Mice Fed the Insoluble Fraction of Brassica rapa L. that was Fermented or Not. Microbes Environ (2017) 0.75
Polydextrose changes the gut microbiome and attenuates fasting triglyceride and cholesterol levels in Western diet fed mice. Sci Rep (2017) 0.75
Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes (2007) 14.12
Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A (2007) 9.71
Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol (2006) 6.09
Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr (1999) 5.12
Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA (2003) 4.76
Dietary fiber, glycemic load, and risk of NIDDM in men. Diabetes Care (1997) 4.46
Carbohydrates, dietary fiber, and incident type 2 diabetes in older women. Am J Clin Nutr (2000) 3.93
Whole grain, bran, and germ intake and risk of type 2 diabetes: a prospective cohort study and systematic review. PLoS Med (2007) 3.91
Whole-grain consumption and risk of coronary heart disease: results from the Nurses' Health Study. Am J Clin Nutr (1999) 3.89
Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care (2006) 3.72
Dietary fibres, fibre analogues, and glucose tolerance: importance of viscosity. Br Med J (1978) 3.54
Dietary fiber, weight gain, and cardiovascular disease risk factors in young adults. JAMA (1999) 3.34
Effect of a low-glycemic index or a high-cereal fiber diet on type 2 diabetes: a randomized trial. JAMA (2008) 3.25
Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus. N Engl J Med (2000) 3.14
Whole-grain intake may reduce the risk of ischemic heart disease death in postmenopausal women: the Iowa Women's Health Study. Am J Clin Nutr (1998) 2.96
Beneficial effects of a Dietary Approaches to Stop Hypertension eating plan on features of the metabolic syndrome. Diabetes Care (2005) 2.76
Dietary fiber and body weight. Nutrition (2005) 2.71
Relation between changes in intakes of dietary fiber and grain products and changes in weight and development of obesity among middle-aged women. Am J Clin Nutr (2003) 2.68
Whole-grain and fiber intake and the incidence of type 2 diabetes. Am J Clin Nutr (2003) 2.62
Dietary fiber and weight regulation. Nutr Rev (2001) 2.61
Long-term pharmacotherapy in the management of obesity. National Task Force on the Prevention and Treatment of Obesity. JAMA (1996) 2.48
Fiber and magnesium intake and incidence of type 2 diabetes: a prospective study and meta-analysis. Arch Intern Med (2007) 2.47
Dietary intake among youth with diabetes: the SEARCH for Diabetes in Youth Study. J Am Diet Assoc (2006) 2.35
Cholesterol-lowering effects of psyllium intake adjunctive to diet therapy in men and women with hypercholesterolemia: meta-analysis of 8 controlled trials. Am J Clin Nutr (2000) 2.21
Effect of whole grains on insulin sensitivity in overweight hyperinsulinemic adults. Am J Clin Nutr (2002) 2.21
Effects of an ad libitum low-fat, high-carbohydrate diet on body weight, body composition, and fat distribution in older men and women: a randomized controlled trial. Arch Intern Med (2004) 2.08
Whole-grain intake and the risk of type 2 diabetes: a prospective study in men. Am J Clin Nutr (2002) 1.96
Treatment of obesity. Lancet (1992) 1.91
Effects of dietary fibers on disturbances clustered in the metabolic syndrome. J Nutr Biochem (2007) 1.89
Effect of wheat bran on glycemic control and risk factors for cardiovascular disease in type 2 diabetes. Diabetes Care (2002) 1.88
Energy density, palatability, and satiety: implications for weight control. Nutr Rev (1998) 1.86
Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia (1993) 1.80
Changes in whole-grain, bran, and cereal fiber consumption in relation to 8-y weight gain among men. Am J Clin Nutr (2004) 1.70
Role of viscous guar gums in lowering the glycemic response after a solid meal. Am J Clin Nutr (1994) 1.65
Cereal, fruit, and vegetable fiber intake and the risk of cardiovascular disease in elderly individuals. JAMA (2003) 1.54
Effect of dietary fiber intake on blood pressure: a randomized, double-blind, placebo-controlled trial. J Hypertens (2004) 1.50
Whole grain consumption and risk of ischemic stroke in women: A prospective study. JAMA (2000) 1.47
Viscous and nonviscous fibres, nonabsorbable and low glycaemic index carbohydrates, blood lipids and coronary heart disease. Curr Opin Lipidol (2000) 1.46
Effect of dietary fiber intake on blood pressure: a meta-analysis of randomized, controlled clinical trials. J Hypertens (2005) 1.40
Gastric sensorimotor functions and hormone profile in normal weight, overweight, and obese people. Gastroenterology (2006) 1.39
Postprandial glucose, insulin, and incretin responses to grain products in healthy subjects. Am J Clin Nutr (2002) 1.38
Diabetes mellitus death-rates in England and Wales 1920-70 and food supplies. Lancet (1974) 1.38
Psyllium as therapeutic and drug delivery agent. Int J Pharm (2007) 1.34
Effect of protein, fat, carbohydrate and fibre on gastrointestinal peptide release in humans. Regul Pept (2008) 1.33
Dietary fiber and body-weight regulation. Observations and mechanisms. Pediatr Clin North Am (2001) 1.31
Gastric emptying in early noninsulin-dependent diabetes mellitus. J Nucl Med (1996) 1.28
In vivo imaging of intragastric gelation and its effect on satiety in humans. J Nutr (2004) 1.28
Crude fibre, dietary fibre and atherosclerosis. Atherosclerosis (1972) 1.26
Signals that influence food intake and body weight. Physiol Behav (2005) 1.22
Low body mass index in non-meat eaters: the possible roles of animal fat, dietary fibre and alcohol. Int J Obes Relat Metab Disord (1998) 1.20
Pectin delays gastric emptying and increases satiety in obese subjects. Gastroenterology (1988) 1.18
Impact of cereal fibre on glucose-regulating factors. Diabetologia (2005) 1.15
Viscous fibers, health claims, and strategies to reduce cardiovascular disease risk. Am J Clin Nutr (2000) 1.14
Mechanisms of the effects of grains on insulin and glucose responses. J Am Coll Nutr (2000) 1.13
Soluble fiber intake at a dose approved by the US Food and Drug Administration for a claim of health benefits: serum lipid risk factors for cardiovascular disease assessed in a randomized controlled crossover trial. Am J Clin Nutr (2002) 1.09
Dietary protein and soluble fiber reduce ambulatory blood pressure in treated hypertensives. Hypertension (2001) 1.07
Postprandial lipid, glucose, insulin, and cholecystokinin responses in men fed barley pasta enriched with beta-glucan. Am J Clin Nutr (1999) 1.06
Guar gum: a miracle therapy for hypercholesterolemia, hyperglycemia and obesity. Crit Rev Food Sci Nutr (2007) 1.06
Impact of nondigestible carbohydrates on serum lipoproteins and risk for cardiovascular disease. J Nutr (1999) 1.05
Whole grain consumption and weight gain: a review of the epidemiological evidence, potential mechanisms and opportunities for future research. Proc Nutr Soc (2003) 1.05
Colonic fermentation of indigestible carbohydrates contributes to the second-meal effect. Am J Clin Nutr (2006) 1.05
Long-term cholesterol-lowering effects of psyllium as an adjunct to diet therapy in the treatment of hypercholesterolemia. Am J Clin Nutr (2000) 1.04
The mechanism of action of guar gum in improving glucose tolerance in man. Clin Sci (Lond) (1984) 1.04
A small dose of soluble alginate-fiber affects postprandial glycemia and gastric emptying in humans with diabetes. J Nutr (1991) 1.03
Alginate as a source of dietary fiber. Crit Rev Food Sci Nutr (2005) 1.03
Therapeutic effects of psyllium in type 2 diabetic patients. Eur J Clin Nutr (2002) 1.01
Effect of psyllium on gastric emptying, hunger feeling and food intake in normal volunteers: a double blind study. Eur J Clin Nutr (1998) 1.01
Whole-grain consumption, dietary fibre intake and body mass index in the Netherlands cohort study. Eur J Clin Nutr (2007) 1.00
The effects of fiber enrichment of pasta and fat content on gastric emptying, GLP-1, glucose, and insulin responses to a meal. Eur J Clin Nutr (2003) 0.98
Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: systematic review and meta-analysis. Am J Clin Nutr (2008) 0.97
Distinct mechanisms of plasma LDL lowering by dietary fiber in the guinea pig: specific effects of pectin, guar gum, and psyllium. J Lipid Res (1995) 0.97
Effect of gel-forming gums on the intestinal unstirred layer and sugar transport in vitro. Gut (1981) 0.97
A flexible, low-glycemic index mexican-style diet in overweight and obese subjects with type 2 diabetes improves metabolic parameters during a 6-week treatment period. Diabetes Care (2003) 0.96
Evening ready-to-eat cereal consumption contributes to weight management. J Am Coll Nutr (2004) 0.96
Effect of glucomannan on obese patients: a clinical study. Int J Obes (1984) 0.95
Effect of hydrolyzed guar fiber on fasting and postprandial satiety and satiety hormones: a double-blind, placebo-controlled trial during controlled weight loss. Int J Obes Relat Metab Disord (1998) 0.93
Lipid- and glucose-lowering efficacy of Plantago Psyllium in type II diabetes. J Diabetes Complications (1998) 0.93
Fermentable and nonfermentable fiber supplements did not alter hunger, satiety or body weight in a pilot study of men and women consuming self-selected diets. J Nutr (2003) 0.93
Effects of agar and pectin on gastric emptying and post-prandial glycaemic profiles in healthy human volunteers. Clin Exp Pharmacol Physiol (2007) 0.93
Effect of bran particle size on gastric emptying and small bowel transit in humans: a scintigraphic study. Gut (1995) 0.92
Long-term effects of dietary fiber on glucose tolerance and gastric emptying in noninsulin-dependent diabetic patients. Am J Clin Nutr (1983) 0.91
Effect of guar gum on body-weight, hunger ratings and metabolism in obese subjects. Br J Nutr (1984) 0.91
Effects of ispaghula husk and guar gum on postprandial glucose and insulin concentrations in healthy subjects. Eur J Clin Nutr (2001) 0.90
Effect of two doses of a mixture of soluble fibres on body weight and metabolic variables in overweight or obese patients: a randomised trial. Br J Nutr (2007) 0.90
Effects of psyllium on glucose and serum lipid responses in men with type 2 diabetes and hypercholesterolemia. Am J Clin Nutr (1999) 0.90
Guar gum for body weight reduction: meta-analysis of randomized trials. Am J Med (2001) 0.90
The stomach signals satiety. Science (1978) 0.90
Is fiber satiating? Effects of a high fiber preload on subsequent food intake of normal-weight and obese young men. Appetite (1986) 0.90
Experiences with three different fiber supplements in weight reduction. Med Sci Monit (2005) 0.89
Overweight treated with energy restriction and a dietary fibre supplement: a 6-month randomized, double-blind, placebo-controlled trial. Int J Obes (1990) 0.89
Daily ingestion of alginate reduces energy intake in free-living subjects. Appetite (2008) 0.88
The botanical integrity of wheat products influences the gastric distention and satiety in healthy subjects. Nutr J (2008) 0.88
Glucomannan, a promising polysaccharide for biopharmaceutical purposes. Eur J Pharm Biopharm (2008) 0.88
Effect of bran, ispaghula, and inert plastic particles on gastric emptying and small bowel transit in humans: the role of physical factors. Gut (1997) 0.87
Long-term effect of fibre supplement and reduced energy intake on body weight and blood lipids in overweight subjects. Acta Medica (Hradec Kralove) (2000) 0.87
Troglitazone effects on gene expression in human skeletal muscle of type II diabetes involve up-regulation of peroxisome proliferator-activated receptor-gamma. J Clin Endocrinol Metab (1998) 0.87
Regulation of hepatic 7 alpha-hydroxylase expression by dietary psyllium in the hamster. J Clin Invest (1994) 0.86
Mechanisms of cholesterol-lowering effects of dietary insoluble fibres: relationships with intestinal and hepatic cholesterol parameters. Br J Nutr (2005) 0.86
Fiber and C-reactive protein in diabetes, hypertension, and obesity. Diabetes Care (2005) 0.86
Fiber intake of normal weight, moderately obese and severely obese subjects. Obes Res (1995) 0.86
Functional gastroduodenal disorders. Gastroenterology (2006) 8.51
AGA technical review on irritable bowel syndrome. Gastroenterology (2002) 6.76
Chronic constipation. N Engl J Med (2003) 4.58
Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. Am J Gastroenterol (2007) 3.65
A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology (2013) 3.56
A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol (2011) 2.81
Independent influences of body mass and gastric volumes on satiation in humans. Gastroenterology (2004) 2.63
Contributions of gastric volumes and gastric emptying to meal size and postmeal symptoms in functional dyspepsia. Gastroenterology (2004) 2.48
Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology (2007) 2.30
A study of candidate genotypes associated with dyspepsia in a U.S. community. Am J Gastroenterol (2006) 2.30
Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol (2012) 2.13
Symptomatic overlap between irritable bowel syndrome and microscopic colitis. Inflamm Bowel Dis (2007) 1.97
Contribution of endogenous glucagon-like peptide 1 to glucose metabolism after Roux-en-Y gastric bypass. Diabetes (2013) 1.90
Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. J Nucl Med Technol (2008) 1.90
Drawing a blank in functional dyspepsia? Gastroenterology (2006) 1.89
Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol (2009) 1.87
Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol (2003) 1.86
Obesity is associated with increased risk of gastrointestinal symptoms: a population-based study. Am J Gastroenterol (2004) 1.86
Rumination syndrome in children and adolescents: diagnosis, treatment, and prognosis. Pediatrics (2003) 1.76
A community-based, controlled study of the epidemiology and pathophysiology of dyspepsia. Clin Gastroenterol Hepatol (2004) 1.75
A system model of oral glucose absorption: validation on gold standard data. IEEE Trans Biomed Eng (2006) 1.66
Gastric accommodation and emptying in evaluation of patients with upper gastrointestinal symptoms. Clin Gastroenterol Hepatol (2003) 1.66
Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol Gastrointest Liver Physiol (2002) 1.58
Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology (2010) 1.53
Effect of alginate on satiation, appetite, gastric function, and selected gut satiety hormones in overweight and obesity. Obesity (Silver Spring) (2009) 1.52
Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol (2008) 1.52
Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation. Expert Rev Gastroenterol Hepatol (2011) 1.47
Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes (2007) 1.47
Gastric sensory and motor dysfunction in adolescents with functional dyspepsia. J Pediatr (2005) 1.46
Developing irritable bowel syndrome guidelines through meta-analyses: does the emperor really have new clothes? Gastroenterology (2009) 1.43
A nutrient drink test to assess maximum tolerated volume and postprandial symptoms: effects of gender, body mass index and age in health. Neurogastroenterol Motil (2002) 1.39
Alterations in mucosal immunity identified in the colon of patients with irritable bowel syndrome. Clin Gastroenterol Hepatol (2008) 1.39
Gastric sensorimotor functions and hormone profile in normal weight, overweight, and obese people. Gastroenterology (2006) 1.39
Urine sugars for in vivo gut permeability: validation and comparisons in irritable bowel syndrome-diarrhea and controls. Am J Physiol Gastrointest Liver Physiol (2011) 1.38
The HIPAA authorization form and effects on survey response rates, nonresponse bias, and data quality: a randomized community study. Med Care (2007) 1.37
Relationship between clinical features and gastric emptying disturbances in diabetes mellitus. Clin Endocrinol (Oxf) (2008) 1.37
Is there an association between GNbeta3-C825T genotype and lower functional gastrointestinal disorders? Gastroenterology (2006) 1.35
Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation. Am J Gastroenterol (2011) 1.33
Effect of daikenchuto (TU-100) on gastrointestinal and colonic transit in humans. Am J Physiol Gastrointest Liver Physiol (2010) 1.32
Determination of gastric emptying in nonobese diabetic mice. Am J Physiol Gastrointest Liver Physiol (2007) 1.28
Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome? Am J Physiol Gastrointest Liver Physiol (2009) 1.24
A new model for dermatitis herpetiformis that uses HLA-DQ8 transgenic NOD mice. J Clin Invest (2004) 1.23
High body mass alters colonic sensory-motor function and transit in humans. Am J Physiol Gastrointest Liver Physiol (2008) 1.22
A Klothoβ variant mediates protein stability and associates with colon transit in irritable bowel syndrome with diarrhea. Gastroenterology (2011) 1.22
Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes. Diabetes Care (2008) 1.20
Phenotypic variation of colonic motor functions in chronic constipation. Gastroenterology (2009) 1.20
Bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol (2013) 1.20
Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health. Am J Physiol Gastrointest Liver Physiol (2003) 1.17
Gastroparesis: clinical update. Am J Gastroenterol (2006) 1.15
Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study. Am J Physiol Gastrointest Liver Physiol (2007) 1.14
Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans. Am J Physiol Gastrointest Liver Physiol (2003) 1.13
Methods for diagnosis of bile acid malabsorption in clinical practice. Clin Gastroenterol Hepatol (2013) 1.12
Psychometric evaluation of patient-reported outcomes in irritable bowel syndrome randomized controlled trials: a Rome Foundation report. Gastroenterology (2009) 1.11
Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study. Am J Gastroenterol (2005) 1.09
Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects. Am J Physiol Gastrointest Liver Physiol (2008) 1.09
Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans. Clin Gastroenterol Hepatol (2003) 1.08
Cannabinoids in intestinal inflammation and cancer. Pharmacol Res (2009) 1.08
Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study. Clin Gastroenterol Hepatol (2005) 1.08
The gastrointestinal tract and glucose tolerance. Curr Opin Clin Nutr Metab Care (2004) 1.07
Effect of gastric volume or emptying on meal-related symptoms after liquid nutrients in obesity: a pharmacologic study. Clin Gastroenterol Hepatol (2005) 1.07
A stable isotope breath test with a standard meal for abnormal gastric emptying of solids in the clinic and in research. Clin Gastroenterol Hepatol (2008) 1.05
Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome. Clin Gastroenterol Hepatol (2007) 1.04
Regional colon transit in patients with dys-synergic defaecation or slow transit in patients with constipation. Gut (2011) 1.04
Gastric motor and sensory functions in obesity. Obes Res (2005) 1.04
A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults. Gastroenterology (2008) 1.03
Methods for measurement of gastric motility. Am J Physiol Gastrointest Liver Physiol (2009) 1.03
Randomized controlled phase Ib study of ghrelin agonist, RM-131, in type 2 diabetic women with delayed gastric emptying: pharmacokinetics and pharmacodynamics. Diabetes Care (2012) 1.02
A concerted decline in insulin secretion and action occurs across the spectrum of fasting and postchallenge glucose concentrations. Clin Endocrinol (Oxf) (2012) 1.02
Irritable bowel syndrome: recent and novel therapeutic approaches. Drugs (2006) 1.01
Defects in GLP-1 response to an oral challenge do not play a significant role in the pathogenesis of prediabetes. J Clin Endocrinol Metab (2011) 1.01
Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans. Am J Physiol Regul Integr Comp Physiol (2008) 1.00
Association of HLA-DQ gene with bowel transit, barrier function, and inflammation in irritable bowel syndrome with diarrhea. Am J Physiol Gastrointest Liver Physiol (2012) 0.99
Recent advances in clinical practice challenges and opportunities in the management of obesity. Gut (2014) 0.98
Effect of oral CCK-1 agonist GI181771X on fasting and postprandial gastric functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol (2004) 0.97
Visceral hypersensitivity. J Clin Gastroenterol (2005) 0.96
A randomised controlled study of the effect of cholinesterase inhibition on colon function in patients with diabetes mellitus and constipation. Gut (2012) 0.94
Pilot study of pyridostigmine in constipated patients with autonomic neuropathy. Clin Auton Res (2008) 0.94
Paraneoplastic autoimmune multiorgan syndrome: 20 years after. Int J Dermatol (2011) 0.94
Recommendations for probiotic use. J Clin Gastroenterol (2006) 0.94
Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects: a pilot study. Diabetes Care (2010) 0.94
Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome. Gastroenterology (2011) 0.94
New-generation 5-HT4 receptor agonists: potential for treatment of gastrointestinal motility disorders. Expert Opin Investig Drugs (2010) 0.93
Feasibility and application of 3-dimensional ultrasound for measurement of gastric volumes in healthy adults and adolescents. J Pediatr Gastroenterol Nutr (2009) 0.93
Obesity does not increase effects of synthetic ghrelin on human gastric motor functions. Gastroenterology (2006) 0.93
Effects of amitriptyline on gastric sensorimotor function and postprandial symptoms in healthy individuals: a randomized, double-blind, placebo-controlled trial. Am J Gastroenterol (2008) 0.92
Definitions and outcome measures of clinical trials regarding opioid-induced constipation: a systematic review. J Clin Gastroenterol (2015) 0.92
Alteration of gastric functions and candidate genes associated with weight reduction in response to sibutramine. Clin Gastroenterol Hepatol (2007) 0.92
Dose-response effect of a beta3-adrenergic receptor agonist, solabegron, on gastrointestinal transit, bowel function, and somatostatin levels in health. Am J Physiol Gastrointest Liver Physiol (2008) 0.92
Effect of different macronutrients in excess on gastric sensory and motor functions and appetite in normal-weight, overweight, and obese humans. Am J Clin Nutr (2007) 0.91
The role of peptide YY in integrative gut physiology and potential role in obesity. Curr Opin Endocrinol Diabetes Obes (2007) 0.91
Pseudo-obstruction in the critically ill. Best Pract Res Clin Gastroenterol (2003) 0.91
The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus. Clin Gastroenterol Hepatol (2013) 0.91
Methods for the assessment of small-bowel and colonic transit. Semin Nucl Med (2012) 0.91
Pharmacogenetics of the effects of colesevelam on colonic transit in irritable bowel syndrome with diarrhea. Dig Dis Sci (2012) 0.90
Functional dyspepsia, upper gastrointestinal symptoms, and transit in children. J Pediatr (2003) 0.90
Gender differences in irritable bowel syndrome. J Gend Specif Med (2002) 0.90
The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study. Clin Endocrinol (Oxf) (2008) 0.90
Relationship of gastric emptying and volume changes after a solid meal in humans. Am J Physiol Gastrointest Liver Physiol (2005) 0.90
The role of pelvic floor dysfunction and slow colonic transit in adolescents with refractory constipation. Am J Gastroenterol (2004) 0.90
Genetics and genotypes in irritable bowel syndrome: implications for diagnosis and treatment. Gastroenterol Clin North Am (2005) 0.89